Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss

M. Tesařová, L. Peterková, M. Šťastná, M. Kolář, L. Lacina, K. Smetana, R. Hynek, J. Betka, A. Vlasák, P. Lukeš, Z. Fík

. 2022 ; 11 (1) : . [pub] 20221223

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Vestibular schwannoma is the most common benign neoplasm of the cerebellopontine angle. It arises from Schwann cells of the vestibular nerve. The first symptoms of vestibular schwannoma include hearing loss, tinnitus, and vestibular symptoms. In the event of further growth, cerebellar and brainstem symptoms, along with palsy of the adjacent cranial nerves, may be present. Although hearing impairment is present in 95% of patients diagnosed with vestibular schwannoma, most tumors do not progress in size or have low growth rates. However, the clinical picture has unpredictable dynamics, and there are currently no reliable predictors of the tumor's behavior. The etiology of the hearing loss in patients with vestibular schwannoma is unclear. Given the presence of hearing loss in patients with non-growing tumors, a purely mechanistic approach is insufficient. A possible explanation for this may be that the function of the auditory system may be affected by the paracrine activity of the tumor. Moreover, initiation of the development and growth progression of vestibular schwannomas is not yet clearly understood. Biallelic loss of the NF2 gene does not explain the occurrence in all patients; therefore, detection of gene expression abnormalities in cases of progressive growth is required. As in other areas of cancer research, the tumor microenvironment is coming to the forefront, also in vestibular schwannomas. In the paradigm of the tumor microenvironment, the stroma of the tumor actively influences the tumor's behavior. However, research in the area of vestibular schwannomas is at an early stage. Thus, knowledge of the molecular mechanisms of tumorigenesis and interactions between cells present within the tumor is crucial for the diagnosis, prediction of tumor behavior, and targeted therapeutic interventions. In this review, we provide an overview of the current knowledge in the field of molecular biology and tumor microenvironment of vestibular schwannomas, as well as their relationship to tumor growth and hearing loss.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003323
003      
CZ-PrNML
005      
20241119081526.0
007      
ta
008      
230413s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines11010032 $2 doi
035    __
$a (PubMed)36672540
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tesařová, Michaela $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic
245    10
$a Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss / $c M. Tesařová, L. Peterková, M. Šťastná, M. Kolář, L. Lacina, K. Smetana, R. Hynek, J. Betka, A. Vlasák, P. Lukeš, Z. Fík
520    9_
$a Vestibular schwannoma is the most common benign neoplasm of the cerebellopontine angle. It arises from Schwann cells of the vestibular nerve. The first symptoms of vestibular schwannoma include hearing loss, tinnitus, and vestibular symptoms. In the event of further growth, cerebellar and brainstem symptoms, along with palsy of the adjacent cranial nerves, may be present. Although hearing impairment is present in 95% of patients diagnosed with vestibular schwannoma, most tumors do not progress in size or have low growth rates. However, the clinical picture has unpredictable dynamics, and there are currently no reliable predictors of the tumor's behavior. The etiology of the hearing loss in patients with vestibular schwannoma is unclear. Given the presence of hearing loss in patients with non-growing tumors, a purely mechanistic approach is insufficient. A possible explanation for this may be that the function of the auditory system may be affected by the paracrine activity of the tumor. Moreover, initiation of the development and growth progression of vestibular schwannomas is not yet clearly understood. Biallelic loss of the NF2 gene does not explain the occurrence in all patients; therefore, detection of gene expression abnormalities in cases of progressive growth is required. As in other areas of cancer research, the tumor microenvironment is coming to the forefront, also in vestibular schwannomas. In the paradigm of the tumor microenvironment, the stroma of the tumor actively influences the tumor's behavior. However, research in the area of vestibular schwannomas is at an early stage. Thus, knowledge of the molecular mechanisms of tumorigenesis and interactions between cells present within the tumor is crucial for the diagnosis, prediction of tumor behavior, and targeted therapeutic interventions. In this review, we provide an overview of the current knowledge in the field of molecular biology and tumor microenvironment of vestibular schwannomas, as well as their relationship to tumor growth and hearing loss.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Peterková, Lenka $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $7 xx0324604
700    1_
$a Šťastná, Monika $u Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Kolář, Michal $u Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic $1 https://orcid.org/0000000245931525
700    1_
$a Lacina, Lukáš $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $u BIOCEV, Biotechnology and Biomedicine Centre, 252 50 Vestec, Czech Republic $u Department of Dermatovenereology, 1st Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000217509933 $7 xx0106429
700    1_
$a Smetana, Karel $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $u BIOCEV, Biotechnology and Biomedicine Centre, 252 50 Vestec, Czech Republic $1 https://orcid.org/0000000278788403 $7 jn20000710554
700    1_
$a Hynek, Radovan $u Institute of Biochemistry and Microbiology, University of Chemistry and Technology, 166 28 Prague, Czech Republic
700    1_
$a Betka, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Vlasák, Aleš $u Department of Neurosurgery, 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic $1 https://orcid.org/000000025724006X
700    1_
$a Lukeš, Petr $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Fík, Zdeněk $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic $1 https://orcid.org/0000000342439727 $7 xx0228899
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 11, č. 1 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36672540 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20241119081523 $b ABA008
999    __
$a ok $b bmc $g 1922865 $s 1189530
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 11 $c 1 $e 20221223 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
LZP    __
$a Pubmed-20230413

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...